logo-loader
Summit Therapeutics PLC

Summit presents DDS-04 data at antibiotic resistance conference

The drug developer presented in vivo proof of concept data for its antibiotics targeting Enterobacteriaceae in animal models of sepsis, pneumonia and UTI

Summit Therapeutics PLC - Summit presents DDS-04 data at Boston drug development conference

Summit Therapeutics PLC (LON:SMMT)(NASDAQ:SUMM) has presented trial data at a US drug conference showing how its new series of antibiotics has high potency against drug-resistant antibiotics on the market.

The drug developer said it had presented in vivo (within living organisms) proof of concept data for its antibiotics targeting Enterobacteriaceae, a type of bacteria, in animal models of sepsis, pneumonia and urinary tract infection (UTI).

The DDS-04 series of series of antibiotics has the promise of combatting Enterobacteriaceae infections that cause more than one million infections annually in the US alone, the company estimated. 

READ: Summit Therapeutics flags potential of new antibiotic to treat drug-resistant gonorrhoea

Summit added that the efficacy data showed the DDS-04 series were comparable to marketed antibiotics in all three disease models, and built on previous in vitro (outside a living organism) studies demonstrating that the new antibiotic class had “high potency” and targeted multiple resistant and non-resistant Enterobacteriaceae strains.

“Currently marketed broad-spectrum antibiotics for Enterobacteriaceae infections are failing patients at an increasingly alarming rate due to rising antibiotic resistance,” said David Roblin, Summit’s president of research & development, in a poster presentation at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance on Thursday. 

He said the DDS-04 series works via a “new mechanism which has the potential to successfully cure patients by overcoming all known bacterial resistance mechanisms”. 

The mechanism involves targeted compounds that act via a novel bacterial target that has been shown to be rapidly bactericidal and highly potent across diverse Enterobacteriaceae strains.

In early afternoon trading on Thursday, Summit shares were steady at 20p.

Quick facts: Summit Therapeutics PLC

Price: £0.22

Market: AIM
Market Cap: £34.51 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics 'taking leadership role' in development of new antibiotics

Summit Therapeutics PLC's (LON:SUMM) Dr Richard Pye speaks to Proactive London's Andrew Scott following a first quarter update on operational progress across the portfolio. Summit's currently developing three flagship treatments; Ridinilazole, designed to treat Clostridium difficile which...

on 13/6/19

2 min read

;